GSK looks to stand out in the se­vere asth­ma space with at-home in­jec­tions for kids 6 to 11 years old

Glax­o­SmithK­line’s block­buster Nu­cala may have been the first IL-5 drug to win mar­ket­ing ap­proval in se­vere asth­ma back in 2015, but new­er ri­vals like As­traZeneca’s Fasen­ra have turned up the heat in re­cent years. Now GSK’s hop­ing an eas­i­er route of ad­min­is­tra­tion for kids will help set it apart from the pack.

The FDA on Mon­day ap­proved a 40 mg pre­filled sy­ringe of Nu­cala for cer­tain kids be­tween 6 and 11 years old, mean­ing they can take the drug at home in­stead of trekking to the doc­tor’s of­fice every four weeks. That makes a big dif­fer­ence for chil­dren with se­vere eosinophilic asth­ma (SEA), who may have trou­ble fit­ting in ap­point­ments around school and care­givers’ jobs, GSK’s US se­nior med­ical lead Tom Cor­bridge told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER